 |
|
Extending treatment after liver transplant may benefit patients with hepatitis C recurrence
November 02, 2009DETROIT - Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.
"We found that patients who achieved a sustained virological response were more likely to have had extended treatment," says Kimberly Brown, M.D., Division head of Gastroenterology at Henry Ford Hospital and senior author of the study.
"In addition, prolonging treatment for 52 weeks after patients were virus negative, resulted in a relapse rate of only 8 percent." This is in contrast to typical relapse rates of 30-35 percent in non transplant patients treated with standard therapy.
Study results will be presented during an oral presentation Oct. 31 at the American Association for the Study of Liver Diseases' Annual Meeting in Boston.
The study looked at 241 consecutive liver transplant patients from 1999-2006. Patients were offered treatment if they tested positive hepatitis C, had recurrent hepatitis C with at least Stage I fibrosis on biopsy, and stable immunosuppression for a minimum of three months. Patients received either non-pegylated interferon tiw or pegylated interferon weekly in combination with ribavirin.
Of the study patients with hepatitis C, 66 were eligible for treatment, and 22 achieved sustained virological response. Only two patients (8 percent) relapsed.
After week 24 of treatment, 35 percent of patients who achieved a sustained virologic response became virus negative.
"These results call into question previous studies which suggested 'stop rules' at weeks 12 and 24 when there is no response to inferferon and ribravirin," says Dr. Brown. "Our results suggest that even if patients are positive at week 24, there is still a 35 percent chance that they can achieve sustained viral clearance. We think this may be beneficial to extend treatment beyond the standard 48 weeks total."
According to the U.S. Department of Health & Human Services, more than 16,000 liver transplants were performed last year and there are currently almost 18,000 Americans on the liver transplant list.
Henry Ford Health System
Study results will be presented during an oral presentation Oct. 31 at the American Association for the Study of Liver Diseases' Annual Meeting in Boston.
The study looked at 241 consecutive liver transplant patients from 1999-2006. Patients were offered treatment if they tested positive hepatitis C, had recurrent hepatitis C with at least Stage I fibrosis on biopsy, and stable immunosuppression for a minimum of three months. Patients received either non-pegylated interferon tiw or pegylated interferon weekly in combination with ribavirin.
Of the study patients with hepatitis C, 66 were eligible for treatment, and 22 achieved sustained virological response. Only two patients (8 percent) relapsed.
After week 24 of treatment, 35 percent of patients who achieved a sustained virologic response became virus negative.
"These results call into question previous studies which suggested 'stop rules' at weeks 12 and 24 when there is no response to inferferon and ribravirin," says Dr. Brown. "Our results suggest that even if patients are positive at week 24, there is still a 35 percent chance that they can achieve sustained viral clearance. We think this may be beneficial to extend treatment beyond the standard 48 weeks total."
According to the U.S. Department of Health & Human Services, more than 16,000 liver transplants were performed last year and there are currently almost 18,000 Americans on the liver transplant list.
Henry Ford Health System
Liver Transplant Current Events and Liver Transplant News RSSLower tacrolimus doses is suitable for living donor liver transplantation with small-for-size graft
Several studies have shown that living donor liver transplant (LDLT) recipients required smaller doses of tacrolimus compared with deceased donor liver transplant (DDLT) patients, which indicated that liver regeneration could affect the metabolism of tacrolimus in LDLT.
First human gets new antibody aimed at hepatitis C virus
Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).
Scientists link immune system's natural killer cells to infant liver disease
Scientists have linked an overactive response by one of the immune system's key weapons against infection - natural killer, or NK, cells - to the onset of biliary atresia in infants, a disease where blocked bile ducts can cause severe liver damage and death.
Mayo Clinic finds new pathology tests double sensitivity to detect bile duct and pancreatic cancers
Pancreatic cancer and bile duct cancer are difficult to diagnose and often fatal because they are discovered in the advanced stages of the disease.
Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
Researchers have discovered a novel molecular path that predisposes patients to develop primary biliary cirrhosis, a disease that mainly affects women and slowly destroys their livers. Primary biliary cirrhosis has no known cause.
What is the function of lymph nodes?
If we imagine our immune system to be a police force for our bodies, then previous work has suggested that the Lymph nodes would be the best candidate structures within the body to act as police stations - the regions in which the immune response is organised.
Novel antibody prevents infection by hepatitis C virus
Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV).
HIV positive and HIV negative patients have similar survival rates following liver transplant
HIV positive and HIV negative patients have comparable survival rates following liver transplant, according to new research presented today at EASL 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark.
Mayo Clinic's new imaging technology accurately identifies a broad spectrum of liver disease
A new study shows that an imaging technology developed by Mayo Clinic researchers can identify liver fibrosis with high accuracy and help eliminate the need for liver biopsies. Liver fibrosis is a common condition that can lead to incurable cirrhosis if not treated in time.
Adult liver transplant eligibility criteria
The pain is debilitating. The only option: smoking medical marijuana. That's the reality for many hepatitis C patients whose road to health includes a liver transplant.
More Liver Transplant Current Events and Liver Transplant News Articles
 |
Medical Care of the Liver Transplant Patient: Total Pre-, Intra- and Post-Operative Management by Paul G Killenberg (Editor), Pierre-Alain Clavien (Editor) Medical Care of the Liver Transplant Patient looks at monitoring and maintaining the health of organ recipients and donors, pre, during and post-operatively. There are twenty-nine chapters containing practical advice on total patient management. They are arranged into 8 sections and follow the stages of transplantation from first indication and selection of potential recipient, through to acute recovery, long-term follow-up and continued health. In this edition there are new chapters on special considerations in liver transplant patients such as viral hepatitis, alcoholic liver disease and live donor liver transplantation. It also contains the very latest information concerning complications and recurring problems after transplantation. Another new chapter considers fresh... |
 |
A&E - Special : Transplant Team Also With: Towers (Producer) Follow four patients whose lives are forever changed by the miracle of transplant surgery: 2-year old Casey, who struggles to survive her multi-organ transplant; 18-year old Angela, born with a congenital heart disease and awaiting a new heart; Patty, undergoing her second liver transplant; and Jaynee, facing a race-against-the-clock heart surgery. We are taken up-close into their world, where we meet the doctors and nurses who care for them and where these patients and their families face the anticipation, the disappointment, the fear and the heartbreak of waiting for a donor, undergoing surgery, rejecting their organ and recovering. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
I'm Glad You're Not Dead : A Liver Transplant Story, 2nd edition by Elizabeth Parr (Author) This book is the second edition of a very popular narrative about the procedure of liver transplantation, told by the author about her own experience. It is often humorous, always informative, targeted at the patient and family who desperately need this information. The book was edited by medical personnel. The second edition has an extended glossary, further treatment of Hepatitis C, and more information about the distribution of organs. Anyone facing transplant or interested in the medical marvel will profit from reading this narrative. |
 |
100 Q&A About Liver Transplantation: A Lahey Clinic Guide (100 Questions & Answers about) by Fredric D. Gordon (Author) Whether you or a loved one is contemplating liver transplantation, on the waiting list for liver transplantation, or are a transplant recipient, the options and information about this surgery can be overwhelming. This invaluable resource offers the guidance and advice you need. Written by a prominent physician, this book gives you authoritative, practical answers to your pre- and post-surgery questions about indications, evaluation, medications and side effects, living donor transplantation, and much more. |
 |
Liver Transplant Survivor Infant Creeper by CafePress |
 |
Liver Transplant Survivor Infant Creeper by CafePress |
 |
Dead Kennedys Ted Kennedy Liver Transplant Live At the Farm San Francisco 1985 Pressing of 500 on Martini Colored Vinyl with Red Pimento Center (LP Vinyl) |
 |
Celebrity Liver Transplants Neil Hamburger (Primary Contributor) |
 |
Sleeping Dogs Lie Starring: Jayma Mays, Dahlia Salem Directed By: Greg Yaitanes Also With: Bryan Singer (Producer), David Shore (Producer), Paul Attanasio (Producer), Katie Jacobs (Producer), Russel Friend (Producer), Garrett Lerner (Producer), Doris Egan (Producer), Thomas L. Moran (Producer), Daniel Sackheim (Producer), Sara Hess (Writer) |
 |
Transplantation of the Liver by Ronald W. Busuttil (Editor), Goran B. Klintmalm (Editor) Spearheaded by two of the world's preeminent experts in liver surgery, the new edition of this landmark masterwork encompasses all of today's best knowledge in the field. It provides detailed discussions of everything from pathophysiology and patient and donor selection...through transplantation anesthesia and full range of operative procedures...to immunosuppression, postoperative care, and ethical issues. The result is an ideal single source for authoritative, up-to-the-minute guidance on every imaginable aspect of liver transplantation. Discusses the background and available management options for each hepatic disease entity. Addresses anesthesia for liver transplantation"oa crucial aspect of successful surgery that is often neglected in other sources. Provides... |
| © 2009 BrightSurf.com |